# The influence of renal function on surgical outcomes of vitrectomy in patients with proliferative diabetic retinopathy

**Authors:** Qiongzhen Yuan, Zhouquan Yang, Wei Fan, Xiaofan Chen, Huan Zou, Rongdi Yuan

PMC · DOI: 10.3389/fendo.2025.1592618 · Frontiers in Endocrinology · 2025-07-16

## TL;DR

This study found that poor kidney function does not worsen surgical outcomes for vitrectomy in patients with a type of diabetic eye disease.

## Contribution

The study demonstrates that impaired renal function does not negatively impact vitrectomy outcomes in proliferative diabetic retinopathy patients.

## Key findings

- Patients with impaired renal function showed greater visual acuity improvement after surgery at multiple follow-up times.
- No significant differences in surgical procedures or complications were observed between the groups.
- Postoperative visual acuity outcomes were similar between groups despite initial differences.

## Abstract

To investigate the influence of renal function on the surgical outcomes of vitrectomy in patients with proliferative diabetic retinopathy (PDR).

A secondary analysis was conducted on data from a retrospective cohort study.

A total of 128 eyes with PDR that underwent pars plana vitrectomy (PPV) and were followed up for at least 2 years were enrolled, including 65 eyes in the impaired renal function (IRF) group and 63 eyes in the normal renal function (NRF) group. No significant between-group differences were observed in the proportion of cataract surgery (p = 0.722), intraoperative retinal photocoagulation (p = 0.476), gas tamponade (p = 0.932), silicone oil tamponade (p = 0.254), retinal dialysis and/or iatrogenic retinal breaks (p = 0.447), and 23- or 25-gauge (G) microincision vitrectomy surgery (MIVS) (p = 0.160). Similarly, intergroup comparisons showed no significant differences in the proportion of reoperation (p = 0.883), postoperative vitreous hemorrhage (VH) and/or retinal detachment (RD) (p = 0.919), postoperative neovascular glaucoma (NVG) (p = 0.600), and postoperative diabetic macular edema (DME) (p = 0.794). Notably, the IRF group had worse baseline best corrected visual acuity (BCVA) (p = 0.039) and showed greater BCVA improvement at 3 months (p = 0.008), 6 months (p = 0.047), 1 year (p = 0.007), 2 years (p = 0.003), 3 years (p = 0.009), and 4 years (p = 0.024) after surgery. However, there was no significant difference in postoperative BCVA between the two groups at each follow-up time (all p > 0.05).

Renal insufficiency does not adversely affect the surgical outcomes of PPV in patients with PDR.

## Linked entities

- **Diseases:** proliferative diabetic retinopathy (MONDO:0001660), diabetic macular edema (MONDO:0004728), neovascular glaucoma (MONDO:0019783), retinal detachment (MONDO:0008375)

## Full-text entities

- **Genes:** VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}
- **Diseases:** stroke (MESH:D020521), bleeding (MESH:D006470), DM (MESH:D003920), NRF (MESH:D058186), vision deterioration (MESH:D014786), NPDR (OMIM:603933), coronary heart disease (MESH:D003327), DME (MESH:D008269), IgA nephropathy (MESH:D005922), glomerulopathy (MESH:D007674), retinopathy (MESH:D058437), retinal breaks (MESH:D012167), ocular damage (MESH:D015817), retinal ischemia (MESH:D012173), DR (MESH:D003930), CKD (MESH:D051436), T2DM (MESH:D003924), MIVS (MESH:D000267), posterior capsular opacification (MESH:D057851), ocular hypertension (MESH:D009798), inflammatory (MESH:D007249), Renal insufficiency (MESH:D051437), end-stage renal disease (MESH:D007676), VH (MESH:D014823), rubeosis iridis (MESH:C538115), threatening (MESH:D000033), blindness (MESH:D001766), neurovascular disease (MESH:D013901), obesity (MESH:D009765), death (MESH:D003643), NVG (MESH:D015355), cataract (MESH:D002386), RD (MESH:D012163), complications (MESH:D008107), proteinuria (MESH:D011507), DN (MESH:D003928), diabetic damage (MESH:D058065), hematuria (MESH:D006417), posterior vitreous detachment (MESH:D020255), insulin-dependent DM (MESH:D003922), hyperglycemia (MESH:D006943), fibrovascular membrane (MESH:D015433), hypertension (MESH:D006973)
- **Chemicals:** cholesterol (MESH:D002784), TC (MESH:D013667), creatinine (MESH:D003404), TG (MESH:D013866), oral antidiabetic medications (-), silicone oil (MESH:D012827), triglyceride (MESH:D014280), uric acid (MESH:D014527), perfluorocarbon (MESH:D005466), silicone (MESH:D012828), aldosterone (MESH:D000450), insulin (MESH:D007328), triamcinolone acetonide (MESH:D014222), urea nitrogen (MESH:C530477)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12308499/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12308499/full.md

## References

46 references — full list in the complete paper: https://tomesphere.com/paper/PMC12308499/full.md

---
Source: https://tomesphere.com/paper/PMC12308499